Long Ideas - On Tuesday, Gattex (teduglutide) received a unanimous recommendation for approval from the FDA’s Gastrointestinal Drugs Advisory Committee, suggesting that the FDA may officially approve the … Continue Reading
Read NowLong Ideas - Developers of potential Hepatitis C (HCV) treatments are among the most-traded in the healthcare industry on Monday, following an announcement from Abbot Laboratories (NYSE:ABT) that … Continue Reading
Read NowLong Ideas - Exelixis (NASDAQ:EXEL) has a Prescription Drug User Fee Act (PDUFA) action date on November 29th, 2012 for cabozantinib as a treatment for patients with progressive, unresectable, … Continue Reading
Read NowLong Ideas - Elan Corp. (NYSE:ELN) is facing headwinds Monday morning after an analyst downgraded the stock based on slowing Tysabri sales growth. Leerink Swann lowered ELN’s price … Continue Reading
Read NowLong Ideas - For most mutual funds, tax-loss selling must be done by the end of Monday. As a result, pressure could come off names that have had … Continue Reading
Read NowLong Ideas - The FDA posted notes Friday for its upcoming Advisory Committee meeting, stating that the governing body is in agreement with NPS Pharmaceuticals (NASDAQ:NPSP) on the … Continue Reading
Read NowLong Ideas - Two pertinent announcements from Lexicon Pharmaceuticals (NASDAQ:LXRX) are giving shares a 7% lift on Friday morning. The company reported top-line data from the latest Phase … Continue Reading
Read Now